Products Description
English name：Dulaglutide
CAS number：923950-08-7
molecular formula
Molecular weight: 0
EINECS No.: 200-001-8
Related categories
GLP-1 type R diabetes mellitus; polypeptide; drug substance; drug polypeptide; mab 9; chemical reagent; GLP
The Mol file: Mol File
structural formula:
Duraglutide properties
Form: liquid
Color: colorless to pale yellow
CAS database: 923950-08-7
Dulullutide
GLP analogs
Duraglutide (trade name: Trulicity), a long-acting GLP-1 analog developed by Eli Lilly, was approved for the treatment of type 2 diabetes in the United States in September 2014. Structurally, dulullutide replaces Gly from Ala at 8 on the GLP-1 (7-37) chain, Glu at position 22, and Gly from Arg at 36Chemicalbook from Arg, with an average biological half-life of up to 90h. In February 2014, clinical results showed that the efficacy of duraglutide was non-inferior to liraglutide, and it was the first macromolecular GLP-1 analogue non-inferior to liraglutide. However, the frequency of duraglutide administered once / w can greatly improve patient compliance, and it is a new product with great potential to compete with liraglutide.
GLP analogs include GLP-1 analogues with GLP-2 analogues. GLP-1 analogues are mainly used for type II diabetes, and the marketed drugs include Chemicalbook senatide, liraglutide, lixisenatide, dulullutide and alpillutide. While GLP-2 analogues are used for short bowel syndrome, only tenulutide is currently available.
GLP-1 analogues are a popular polypeptide field, with peptide chain length between 31 and 44 amino acids and no disulfide bonds within the structure. The main popular Chemicalbook models for GLP-1 analogues are liraglutide and exenatide, with combined sales of more than $3 billion. Some analysts expect the market for GLP-1 analogues to exceed $6 billion in five years
Polypeptide
Duraglutide, a novel long-acting GLP-1R agonist, was obtained by two GLP-1 analogues with DPP-4 inhibition and fusion of human immunoglobulin heavy chain IgG 4-Fc fragment, with similar activity to endogenous GLChemicalbookP-1 in clinical manifestations and a half-life of 5 days, and can effectively delay the renal clearance. FDA approved Dulagutide in September 2014. The European Commission approved dulaglutide subcutaneous injection for marketing in Europe in December 2014.
Hot Tags: dulaglutide is a glucagon-like peptide-1 receptor agonist, China dulaglutide is a glucagon-like peptide-1 receptor agonist suppliers, first interchangeable biosimilar, Trastuzumab an antitumor drug, biosimilar for herceptin, Pembrolizumab inhibitors, Ocrelizumab inhibitors, Ipilimumab inhibitors
